Compare SLDP & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDP | AGMB |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | Belgium |
| Employees | 230 | 62 |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.0M | 562.4M |
| IPO Year | N/A | N/A |
| Metric | SLDP | AGMB |
|---|---|---|
| Price | $3.03 | $11.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 6.0M | 64.9K |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.90 | $17.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.40 | $9.00 |
| 52 Week High | $8.86 | $17.45 |
| Indicator | SLDP | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 51.68 |
| Support Level | $2.86 | $9.62 |
| Resistance Level | $3.22 | $12.29 |
| Average True Range (ATR) | 0.22 | 0.93 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 46.52 | 36.97 |
Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.